Headlines about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.4348295549472 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s rankings:
- Aldeyra Therapeutics (ALDX) Given Buy Rating at Canaccord Genuity (americanbankingnews.com)
- Aldeyra Therapeutics (ALDX) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS (americanbankingnews.com)
- Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update (finance.yahoo.com)
- Aldeyra Therapeutics (ALDX) PT Set at $23.00 by Cantor Fitzgerald (americanbankingnews.com)
Shares of ALDX traded up $0.30 during trading hours on Friday, hitting $7.75. 85,382 shares of the company were exchanged, compared to its average volume of 87,102. The company has a market cap of $155.27 million, a PE ratio of -5.54 and a beta of 0.45. Aldeyra Therapeutics has a 52 week low of $3.90 and a 52 week high of $11.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.09 and a current ratio of 11.09.
A number of research analysts have commented on the company. ValuEngine downgraded Aldeyra Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 30th. Cantor Fitzgerald restated a “buy” rating and issued a $23.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, June 26th. Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 21st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $27.00 price target on shares of Aldeyra Therapeutics in a research note on Friday. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $16.90.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.